Takeda Acquires Ariad In $5.2bn Deal – US Infrastructure A Key Component?
Executive Summary
Takeda will pay $5.2bn to buy Ariad Pharmaceuticals, the developer of one marketed cancer therapy, Iclusig – but the latter firm's US location and operations could be other important draws for the Japanese big pharma, which has previously announced plans to overhaul its own R&D activities.
You may also be interested in...
Takeda’s Iclusig Looks Set To Become SOC In First-Line Ph+ Acute Lymphoblastic Leukemia
The drug beat out imatinib on efficacy while not drawing any increased concerns about safety, and an investigator told Scrip it should replace imatinib as first-line standard of care in the rare ALL subtype.
Takeda: 12 NMEs Poised To Launch In Five Years, And Deliver $10 Bn In Peak Sales
The Japanese pharma held its first investor day in New York, outlining the company's strategy to deliver long-term growth through a newly energized oncology, gastrointestinal and rare disease pipeline.
BIO 2019 Notebook: Sharpless On Pricing, Marks On Gene Therapy, Takeda On M&A
News and views from day two of the BIO International Convention: US FDA's Sharpless decries the focus on the price of "medical miracle" Zolgensma; CBER Director Marks talks about how his division will staff up to review cell and gene therapy candidates; and Takeda explains why its business development philosophy leads to the valuation seen in the Ariad buyout.